Re: I think we're over the hump
>>>>>I interpret that to be Andexxa is no 5 on the list, which is fine
As I stated before, I think SG made an excellent point referring to their study and changes the perception of the slow ramp up. #5 is more than just fine, if they can keep on that trajectory A will be a $1 billion blockbuster.
>>>>>Hard to get excited when they pointedly did not name the country. I am optimistic about Europe, but I think appreciable sales are still a ways off.
From the conference call transcript they did name the countries:
“As you know, launching in Europe is a country-by-country process and it happens in stages. These first sales in Austria and the U.K. mark our official launch and the availability of Ondexxya for ordering in Austria, the U.K., the Netherlands, Sweden, Denmark and Finland. Germany is also part of our Wave 1 launch, and we expect Ondexxya to be available there later this year.”